Amalgamated Bank’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.82M Sell
22,281
-678
-3% -$49K 0.01% 882
2026
Q1
$1.56M Sell
22,959
-163
-0.7% -$11.5K 0.01% 904
2025
Q4
$1.76M Buy
23,122
+20,604
+818% +$1.5M 0.01% 871
2025
Q3
$155K Sell
2,518
-119
-5% -$6.2K ﹤0.01% 1629
2025
Q2
$129K Hold
2,637
﹤0.01% 1657
2025
Q1
$134K Buy
2,637
+108
+4% +$5.39K ﹤0.01% 1621
2024
Q4
$114K Hold
2,529
﹤0.01% 1676
2024
Q3
$94K Hold
2,529
﹤0.01% 1717
2024
Q2
$77K Buy
2,529
+125
+5% +$4.05K ﹤0.01% 1767
2024
Q1
$70K Sell
2,404
-7,088
-75% -$199K ﹤0.01% 1788
2023
Q4
$262K Sell
9,492
-715
-7% -$16.4K ﹤0.01% 1712
2023
Q3
$229K Buy
10,207
+190
+2% +$7.07K ﹤0.01% 1739
2023
Q2
$407K Buy
10,017
+677
+7% +$33.1K ﹤0.01% 1530
2023
Q1
$452K Sell
9,340
-1,590
-15% -$72.7K ﹤0.01% 1466
2022
Q4
$417K Buy
10,930
+184
+2% +$7.65K ﹤0.01% 1548
2022
Q3
$539K Buy
10,746
+155
+1% +$7.59K 0.01% 1394
2022
Q2
$424K Sell
10,591
-779
-7% -$27.3K ﹤0.01% 1537
2022
Q1
$424K Sell
11,370
-854
-7% -$32.9K ﹤0.01% 1625
2021
Q4
$487K Sell
12,224
-131
-1% -$5.01K ﹤0.01% 1593
2021
Q3
$460K Sell
12,355
-761
-6% -$31.3K ﹤0.01% 1625
2021
Q2
$554K Buy
13,116
+4,317
+49% +$185K ﹤0.01% 1591
2021
Q1
$417K Sell
8,799
-860
-9% -$51.1K 0.02% 1077
2020
Q4
$589K Buy
9,659
+50
+0.5% +$2.95K 0.02% 862
2020
Q3
$449K Sell
9,609
-278
-3% -$13.7K 0.02% 902
2020
Q2
$502K Sell
9,887
-913
-8% -$44.9K 0.02% 835
2020
Q1
$482K Sell
10,800
-338
-3% -$17K 0.01% 931
2019
Q4
$535K Buy
11,138
+990
+10% +$42.1K 0.01% 1079
2019
Q3
$343K Sell
10,148
-127
-1% -$5.53K 0.01% 1236
2019
Q2
$462K Buy
10,275
+2,753
+37% +$109K 0.01% 1110
2019
Q1
$283K Buy
7,522
+890
+13% +$29.9K 0.01% 1303
2018
Q4
$228K Buy
+6,632
New +$238K 0.01% 1334
2018
Q3
Sell
-6,896
Closed -$233K 1583
2018
Q2
$233K Buy
+6,896
New +$215K 0.01% 1471

Other funds holding PTCT

Amalgamated Bank's PTCT Position: Q2 2026 in Review

Amalgamated Bank reduced its PTC Therapeutics (PTCT) stake by 3% in Q2 2026, selling an estimated $49K and leaving 22,281 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #882.

Amalgamated Bank first reported a position in PTCT in Q2 2018 and has held it in 32 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Amalgamated Bank held 22,281 shares of PTC Therapeutics worth $1.82M as of Q2 2026.
  • Amalgamated Bank sold 678 PTC Therapeutics shares in Q2 2026, an estimated $49K.
  • PTC Therapeutics made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #882 holding.
  • Amalgamated Bank first reported a position in PTC Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.